Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Thrombectomy Under Reopro Versus Alteplase to Treat Stoke
NCT02016547 · SOS Attaque Cérébrale · PHASE4 · terminated · last registry update 2014-04-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, SOS Attaque Cérébrale |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-04-21Also stopped (terminated): Neuroscience Trials Australia, intravenous tissue plasminogen activator (tPA) (NCT01492725)
- 2015-04-07Also stopped (terminated): Cerevast Therapeutics, Inc., Standard of care tPA therapy for acute ischemic stroke (NCT01098981)
- 2015-03-25Phase 3 first posted: University of Calgary, Tenecteplase + Antiplatelet treatment (NCT02398656)
- 2015-03-17Also stopped (terminated): University of Virginia, tenecteplase + tissue plasminogen activator, tPA (NCT00252239)
- 2015-02-26Results posted on the registry: Kaiser Permanente, Alteplase (NCT00284739)
- 2015-01-19Results posted on the registry: University of Virginia, tenecteplase + tissue plasminogen activator, tPA (NCT00252239)
- 2015-01-06Results posted on the registry: Kaiser Permanente, normal saline + TNK (Tenecteplase) (NCT01580618)
- 2014-11-26Phase 3 first posted: Supergene, LLC, Recombinant staphylokinase + Tenecteplase (NCT02301910)
- 2014-08-11Results posted on the registry: Wake Forest University Health Sciences, Tenecteplase + Enoxaparin + 0.9% Saline + Enoxaparin (NCT00680628)
- 2014-07-02Phase 3 first posted: Reza Behrouz, DO, Tenecteplase + Alteplase (NCT02180204)
- 2014-02-26Phase 3 first posted: Genentech, Inc., Alteplase + Alteplase Placebo (NCT02072226)
- 2013-12-05Phase 3 first posted: National Cerebral and Cardiovascular Center, Japan, Tissue-type plasminogen activator (alteplase) (NCT02002325)
- 2013-10-09Phase 3 first posted: Boehringer Ingelheim, Actilyse + Saline solution (NCT01958164)
- 2013-09-25Phase 3 first posted: Lars Thomassen, Tenecteplase + Alteplase (NCT01949948)
- 2013-05-24Phase 3 first posted: Children's Mercy Hospital Kansas City, tPA alone + tPA plus dornase (NCT01862458)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision